153 related articles for article (PubMed ID: 34864570)
1. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.
Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
[TBL] [Abstract][Full Text] [Related]
2. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
3. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
Tao Z; Cui Y; Xu X; Han T
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
[TBL] [Abstract][Full Text] [Related]
4. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
Poh W; Wong W; Ong H; Aung MO; Lim SG; Chua BT; Ho HK
Mol Cancer; 2012 Mar; 11():14. PubMed ID: 22439738
[TBL] [Abstract][Full Text] [Related]
5. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
[TBL] [Abstract][Full Text] [Related]
7. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
9. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
10. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
12. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
Jin Q; Zhang D; Gao M; Jiang C; Zhang J
Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
15. Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma.
Rezende Miranda R; Fu Y; Chen X; Perino J; Cao P; Carpten J; Chen Y; Zhang C
J Med Chem; 2020 Oct; 63(20):11484-11497. PubMed ID: 33030342
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.
Gauglhofer C; Paur J; Schrottmaier WC; Wingelhofer B; Huber D; Naegelen I; Pirker C; Mohr T; Heinzle C; Holzmann K; Marian B; Schulte-Hermann R; Berger W; Krupitza G; Grusch M; Grasl-Kraupp B
Carcinogenesis; 2014 Oct; 35(10):2331-8. PubMed ID: 25031272
[TBL] [Abstract][Full Text] [Related]
17. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.
Yang F; Lin Q; Song X; Huang H; Chen X; Tan J; Li Y; Zhou Y; Tu Z; Du H; Zhang ZM; Ortega R; Lin X; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2024 Feb; 67(4):2667-2689. PubMed ID: 38348819
[TBL] [Abstract][Full Text] [Related]
19. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract][Full Text] [Related]
20. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma.
Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]